Company intelligence / Profile preview

MindDay

New York, New York, United States

Ownership: Private
Development stage: Commercial

Overview

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Its lead asset, MM120 ODT (Lysergide D-tartrate), is in Phase 3 trials for generalized anxiety disorder and will enter Phase 3 for major depressive disorder in H1 2025. Another candidate, MM402 ((R)-(-)-MDMA), is in Phase 1 for autism spectrum disorder. The company has reported statistically significant improvements in GAD scores with its lead program

Therapeutic areas: Psychiatry
Modalities: Small moleculePsychedelic-based therapy (psychoplastogen)Non-hallucinogenic small molecule (for 18-MC)
Industry: Biotech

Beyond the preview

Go deeper on MindDay.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MindDay.

Explore the full profile